Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
182.39B
Market cap182.39B
Price-Earnings ratio
23.76
Price-Earnings ratio23.76
Dividend yield
2.86%
Dividend yield2.86%
Average volume
2.38M
Average volume2.38M
High today
$337.99
High today$337.99
Low today
$337.98
Low today$337.98
Open price
$335.00
Open price$335.00
Volume
2.97K
Volume2.97K
52 Week high
$391.29
52 Week high$391.29
52 Week low
$261.43
52 Week low$261.43

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $337.98. The company's market cap stands at 182.39B, with a P/E ratio of 23.76 and a dividend yield of 2.9%.

On 2026-04-30, Amgen(AMGN) stock moved within a range of $337.98 to $337.99. With shares now at $337.98, the stock is trading 0.0% above its intraday low and -0.0% below the session's peak.

Trading volume for Amgen(AMGN) stock has reached 2.97K, versus its average volume of 2.38M.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

Over the past 52 weeks, Amgen(AMGN) stock has traded between a high of $391.29 and a low of $261.43.

AMGN News

Simply Wall St 8h
FDA Tavneos Proposal Puts Amgen Trial Integrity And Growth Story Under Review

The FDA's Center for Drug Evaluation and Research has proposed that Amgen withdraw its drug Tavneos, citing untrue statements of material facts and possible dat...

FDA Tavneos Proposal Puts Amgen Trial Integrity And Growth Story Under Review
Seeking Alpha 20h
Amgen Q1 Preview: What to expect

Amgen (AMGN) is projected to report a nearly 3% fall in its Q1 earnings on April 30, after the closing bell. The consensus EPS Estimate is $4.77, while the rev...

Amgen Q1 Preview: What to expect
TipRanks 2d
FDA Recruits AstraZeneca, Amgen in Bet on AI to Accelerate Drug Development

The U.S. Food and Drug Administration (FDA) is looking to deploy artificial intelligence to achieve real-time evaluation of clinical trial results to accelerate...

Analyst ratings

51%

of 37 ratings
Buy
40.5%
Hold
51.4%
Sell
8.1%

More AMGN News

Seeking Alpha 2d
Amgen faces U.S. withdrawal of rare disorder therapy Tavneos

The U.S. FDA has proposed to withdraw the marketing of Tavneos, a treatment developed by Amgen (AMGN) for a group of rare disorders called anti-neutrophil cytop...

Amgen faces U.S. withdrawal of rare disorder therapy Tavneos
TipRanks 7d
Amgen Marks Key Milestone With Completion of Early MTAP-Null Cancer Combo Study

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.